Journal article
Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)
K Thriemer, TS Degaga, M Christian, MS Alam, B Ley, MS Hossain, MG Kibria, TT Tego, DT Abate, S Weston, A Karahalios, M Rajasekhar, JA Simpson, A Rumaseb, H Mnjala, G Lee, RT Anose, FG Kidane, A Woyessa, K Baird Show all
Trials | Published : 2022
Abstract
Background: Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and onward transmission of the parasite. There is an increased risk of P. vivax parasitaemia following falciparum malaria suggesting a rationale for universal use of radically curative treatment in patients with P. falciparum malaria even in the absence of detectable P. vivax parasitaemia in areas that are co-endemic for both species. Methods: This is a multicentre, health care facility-based, randomized, controlled, open-label..
View full abstractGrants
Awarded by Australian Government
Funding Acknowledgements
Funding for this project is provided by the Australian Academy of Science, on behalf of the Department of Industry, Innovation and Science. The Regional Collaborations Programme is supported by the Australian Government under the National Innovation and Science Agenda. This work is also supported, in part, by the Bill & Melinda Gates Foundation INV-010504 and the Australian National Health and Medical Research Council (NHMRC) Program grant (APP1132975). All published materials are solely the responsibility of the Administering Institution, a Participating Institution or individual authors and do not reflect the views of NHMRC. The funders had no role in the design of the study and are not involved in data collection, analysis, interpretation of data and in writing of the manuscript.